Cardiovascular effects of intravenous tolmesoxide in hypertensive patients.
Tolmesoxide, a potent vasodilating compound, was infused intravenously (0.5 to 3.5 mg/kg b.w., rate of infusion: 2.5 to 10.0 mg/min during 7--25 min, 2 or 3 successive infusions separated by a 30 min rest period) in 7 hypertensive patients. An abrupt fall in blood pressure and heart rate occurred in 4 patients whereas 2 patients exhibited almost no hemodynamic response. The remaining case suffering from renovascular hypertension responded with a progressive dose-dependent decrease in blood pressure. No obvious correlation could be demonstrated between the drug plasma levels (ranging between 1.0 and 11.1 microgram/ml) and the hemodynamic effects among the 7 patients studied.
D000328:Adult; D000959:Antihypertensive Agents / Q000494:pharmacology*; D001786:Blood Glucose / Q000378:metabolism; D003981:Diazoxide / Q000494:pharmacology; D005260:Female; D005934:Glucagon / Q000097:blood; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D006973:Hypertension / Q000503:physiopathology*; D007328:Insulin / Q000097:blood; D008297:Male; D008875:Middle Aged; D013454:Sulfoxides / Q000494:pharmacology*; D014050:Toluene / Q000031:analogs & derivatives* / Q000494:pharmacology
D000959:Antihypertensive Agents; D001786:Blood Glucose; D007328:Insulin; D013454:Sulfoxides; D014050:Toluene; D005934:Glucagon; C016152:tolmesoxide; D003981:Diazoxide